WY 14643, a potent exogenous PPAR-α ligand, reduces intestinal injury associated with splanchnic artery occlusion shock

Shock

Volumn 22, Issue 4, 2004, Pages 340-346

  Cuzzocrea, Salvatore ^a   Di Paola, Rosanna ^a   Mazzon, Emanuela ^a   Genovese, Tiziana ^a   Muià, Carmelo ^a   Caputi, Achille P ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

Ischemia reperfusion shock; PARP ; Splanchnic artery occlusion; WY 14643

Indexed keywords

3 NITROTYROSINE; ADENOSINE DIPHOSPHATE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; MYELOPEROXIDASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PADGEM PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PIRINIXIC ACID; POLY(ADENOSINE DIPHOSPHATE RIBOSE); RETINOID; STEROID; THYROID HORMONE RECEPTOR; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERY CLAMP; ARTICLE; CELIAC ARTERY; CELIAC ARTERY STENOSIS; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; GENE TARGETING; HYPOTENSION; ILEUM DISEASE; IMMUNOREACTIVITY; INTESTINE INJURY; INTESTINE ISCHEMIA; ISCHEMIA; MALE; MEAN ARTERIAL PRESSURE; MORTALITY; NEUTROPHIL; NONHUMAN; RAT; REPERFUSION; REPERFUSION INJURY; SHOCK; SPLANCHNIC ARTERY OCCLUSION SHOCK; SPLANCHNIC BLOOD FLOW; STAINING; SUPERIOR MESENTERIC ARTERY; SUPERIOR MESENTERIC ARTERY OBSTRUCTION; SURVIVAL RATE; TISSUE INJURY; TRANSCRIPTION REGULATION;

ANIMALS; BLOOD PRESSURE; ILEUM; IMMUNOHISTOCHEMISTRY; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-1; MALE; NEUTROPHILS; P-SELECTIN; PEROXIDASE; PEROXISOME PROLIFERATORS; POLY(ADP-RIBOSE) POLYMERASES; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; REPERFUSION INJURY; SHOCK; SPLANCHNIC CIRCULATION; TUMOR NECROSIS FACTOR-ALPHA; TYROSINE; UP-REGULATION;

EID: 7944235591     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.shk.0000136704.26372.2d     Document Type: Article

References (36)

1. Evans RM: The steroid and thyroid hormone receptor superfamily. Science 240:889-895, 1988.
2. Moras D, Gronemeyer H: The nuclear receptor ligand-binding domain: structure and function. Curr Opin Cell Biol 10:384-391, 1998.
3. Murphy GJ, Holder JC: PPAR-gamma agonists: therapeutic role in diabetes, inflammation and cancer. Trends Pharmacol Sci 21:469-474, 2000.
4. Desvergne B, Wahli W: Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 20:649-688, 1999.
5. Wayman NS, McDonald MC, Threadgill MD, Thiemermann C: 5 Amino isoquinolinone, a potent inhibitor of poly (adenosine 5′-diphosphate ribose) polymerase, reduces myocardial infarct size. Eur J Pharmacol 430:93-100, 2001.
6. Sher T, Yi HF, McBride OW, Gonzalez FJ: cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor. Biochemistry 32:5598-5604, 1993.
7. Spiegelman BM: PPAR-γ: adipogenic regulator and thiazolidinedione receptor. Diabetes 47:507-514, 1998.
8. Murphy GJ, Holder JC: PPAR-γ agonists: therapeutic role in diabetes, inflammation and cancer. Trends Pharmacol Sci 21:469-474, 2000.
9. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA: Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 272:3406-3410, 1997.
10. Young PW, Buckle DR, Cantello BC, Chapman H, Clapham JC, Coyle PJ, Haigh D, Hindley RM, Holder JC, Kallender H, Latter AJ, Lawrie KW, Mossakowska D, Murphy GJ, Roxbee CL, Smith SA: Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor γ. J Pharmacol Exp Ther 284:751-759, 1998.
11. Willson TM, Brown PJ, Sternbach DD, Henke BR: The PPARs: from orphan receptors to drug discovery. J Med Chem 43:527-550, 2000.
12. Nakajima A, Wada K, Miki H, Kubota N, Nakajima N, Terauchi Y, Ohnishi S, Saubermann LJ, Kadowaki T, Blumberg RS, Nagai R, Matsuhashi N: Endogenous PPAR γ mediates anti-inflammatory activity in murine ischemia-reperfusion injury. Gastroenterology 1120:460-469, 2001.
13. 2, ligands of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), reduce ischaemia/reperfusion injury of the gut. Br J Pharmacol 140:366-376, 2003.
14. Ito K, Shimada J, Kato D, Toda S, Takagi T, Naito Y, Yoshikawa T, Kitamura N: Protective effects of preischemic treatment with pioglitazone, a peroxisome proliferator-activated receptor-gamma ligand, on lung ischemia-reperfusion injury in rats. Eur J Cardiothorac Surg 25:530-536, 2004.
15. Liu HR, Tao L, Gao E, Lopez BL, Christopher TA, Willette RN, Ohlstein EH, Yue TL, Ma XL: Anti-apoptotic effects of rosiglitazone in hypercholesterolemic rabbits subjected to myocardial ischemia and reperfusion. Cardiovasc Res 62:135-144, 2004.
16. Ito H, Nakano A, Kinoshita M, Matsumori A: Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates myocardial ischemia/reperfusion injury in a rat model. Lab Invest 83:1715-1721, 2003.
17. Yue TL, Bao W, Jucker BM, Gu JL, Romanic AM, Brown PJ, Cui J, Thudium DT, Boyce R, Burns-Kurtis CL, Mirabile RC, Aravindhan K, Ohlstein EH: Activation of peroxisome proliferator-activated receptor-alpha protects the heart from ischemia/reperfusion injury. Circulation 108:2393-2399, 2003.
18. Wayman NS, Ellis BL, Thiemermann C: Ligands of the peroxisome proliferator-activated receptor-PPAR-a reduce myocardial infarct size. Med Sci Monit 8:BR243-BR247, 2002.
19. Sivarajah A, Chatterjee PK, Patel NS, Todorovic Z, Hattori Y, Brown PA, Stewart KN, Mota-Filipe H, Cuzzocrea S, Thiemermann C: Agonists of peroxisome-proliferator activated receptor-gamma reduce renal ischemia/reperfusion injury. Am J Nephrol 23:267-276, 2003.
20. Sivarajah A, Chatterjee PK, Hattori Y, Brown PA, Stewart KN, Todorovic Z, Mota-Filipe H, Thiemermann C: Agonists of peroxisome-proliferator activated receptor-alpha (clofibrate and WY14643) reduce renal ischemia/reperfusion injury in the rat. Med Sci Monit 8:BR532-BR539, 2002.
21. Portilla D, Dai G, Peters JM, Gonzalez FJ, Crew MD, Proia AD: Etomoxir-induced PPARalpha-modulated enzymes protect during acute renal failure. Am J Physiol Renal Physiol 278:F667-F675, 2000.
22. Okaya T, Lentsch AB: Peroxisome proliferator-activated receptor-alpha regulates postischemic liver injury. Am J Physiol Gastrointest Liver Physiol 286:G606-G612, 2004.
23. 2 against the multiple organ failure caused by endotoxin. Crit Care Med 32:826-831, 2004.
24. 2 reduces the liver injury in endotoxic shock. Eur J Pharmacol 476:257-258, 2003.
25. Hill MR, Clarke S, Rodgers K, Thornhill B, Peters JM, Gonzalez FJ, Gimble JM: Effect of peroxisome proliferator-activated receptor alpha activators on tumor necrosis factor expression in mice during endotoxemia. Infect Immun 67:3488-3493, 1999.
26. Cuzzocrea S, Riley DP, Caputi AP, Salvemini D: Antioxidant therapy: a new pharmacological approach in shock, inflammation, and ischemia/reperfusion injury. Pharmacol Rev 53:135-159, 2001.
27. Krook A, Digby J, O'Rahilly S, Zierath JR, Wallberg-Henriksson H: Uncoupling protein 3 is reduced in skeletal muscle of NIDDM patients. Diabetes 47:1528-1531, 1998.
28. Chinetti G, Fruchart JC, Staels B: Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res 49:497-505, 2000.
29. Kleemann R, Gervois PP, Verschuren L, Staels B, Princen HM, Kooistra T: Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFkappa B-C/EBP-beta complex formation. Blood 101:545-551, 2002.
30. Gervois P, Vu-Dac N, Kleemann R, Kockx M, Dubois G, Laine B, Kosykh V, Fruchart JC, Kooistra T, Staels B: Negative regulation of human fibrinogen gene expression by peroxisome proliferator-activated receptor alpha agonists via inhibition of CCAAT box/enhancer-binding protein beta. J Biol Chem 276:33471-33477, 2001.
31. Izumi T, Saito Y, Kishimoto I, Harada M, Kuwahara K, Hamanaka I, Takahashi N, Kawakami R, Li Y, Takemura G, Fujiwara H, Garbers DL, Mochizuki S, Nakao K: Blockade of the natriuretic peptide receptor guanylyl cyclase-A inhibits NF-kappaB activation and alleviates myocardial ischaemia/reperfusion injury. J Clin Invest 108:203-213, 2001.
32. Zingarelli B, Hake PW, Denenberg A, Wong HR: Sesquiterpene lactone parthenolide, an inhibitor of IkappaB kinase complex and nuclear factor-kappaB, exerts beneficial effects in myocardial reperfusion injury. Shock 17:127-134, 2002.
33. Cuzzocrea S, Mazzon E, Dugo L, Serraino I, Centorrino T, Ciccolo A, Van de Loo FA, Britti D, Caputi AP, Thiemermann C: Inducible nitric oxide synthase-deficient mice exhibit resistance to the acute pancreatitis induced by cerulein. Shock 17:416-422, 2002.
34. Cuzzocrea S, Dugo L, Patel NS, Di Paola R, Cockerill GW, Genovese T, Thiemermann C: High-density lipoproteins reduce the intestinal damage associated with ischemia/reperfusion and colitis. Shock 21:342-351, 2004.
35. Cuzzocrea S, McDonald MC, Mazzon E, Filipe HM, Costantino G, Caputi AP, Thiemermann C: Beneficial effects of tempol, a membrane-permeable radical scavenger, in a rodent model of splanchnic artery occlusion and reperfusion. Shock 14:150-156, 2000.
36. Mazzon E, Dugo L, De SA, Li JH, Caputi AP, Zhang J, Cuzzocrea S: Beneficial effects of GPI 6150, an inhibitor of poly(ADP-ribose) polymerase in a rat model of splanchnic artery occlusion and reperfusion. Shock 17:222-221, 2002.